Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
NCT06608901 · View on ClinicalTrials.gov ↗
Study Summary
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during the stay in the hospital. The study is looking at several other research questions, including: * How the study drug changes the blood pressure and the amount of intravenous (IV) fluids given to participants with low blood pressure due to sepsis * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG REGN7544
- DRUG PB
Study Locations (20)
New York
- New York University Langone Health Brooklyn Hospital — Brooklyn
- Bellevue Hospital — New York
- New York University Langone Health Tisch-Kimmel Hospital — New York
- Montefiore Medical Center - Weiler Hospital — The Bronx
- Montefiore Medical Center - Moses Campus — The Bronx
Massachusetts
- Massachusetts General Hospital — Boston
- Harvard Medical School - Beth Israel Deaconess Medical Center — Boston
Arizona
- University of Arizona — Tucson
Connecticut
- Yale University — New Haven
Georgia
- Emory University Hospital — Atlanta
Maryland
- Johns Hopkins Hospital — Baltimore
North Carolina
- Atrium Health — Winston-Salem
Ohio
- Cleveland Clinic Foundation — Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06608901
The ClinicalTrials.gov registry entry for NCT06608901 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 290 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Sepsis-Induced Hypotension appearing as the primary indexed condition, and to 2 interventions — of which REGN7544 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06608901 reports 20 study locations spanning 15 distinct geographic areas — top geographies include New York, Massachusetts, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06608901 about?
NCT06608901 is a clinical study titled "A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension". This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sep...
What is the current status of trial NCT06608901?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2025-05-05. Estimated completion is 2026-04-30.
What conditions does trial NCT06608901 study?
This clinical trial studies the following conditions: Sepsis-Induced Hypotension. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06608901?
The interventions under investigation include: REGN7544 (DRUG), PB (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06608901?
This trial is sponsored by Regeneron Pharmaceuticals, which has 290 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06608901 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.